Clinical trials: Human Papillomavirus Infection
Cervical Cancer, Condylomata Acuminata
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in…
- Trial name
- NCT05056402
- Testing
- 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- Where
- China
- Volunteers
- 1,382 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Human Papillomavirus Infection
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
HPV infection is associated with cervical and other anogenital cancers. HPV may also be associated with the development of prostate cancer.
- Trial name
- NCT01265212
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sanford Health
Infections, Papillomavirus
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1…
- Trial name
- NCT00549900
- Testing
- GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Vulvar Cancer
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04422366
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Genital Warts
Alternate Dosing Schedules Study for HPV Vaccine
To determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicits an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as…
- Trial name
- ADS (NCT00862810)
- Testing
- Received HPV vaccine first, Received concomitant vaccines first
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Duke University
Cervical Cancer, Cervical Dysplasia
Self-sampling for Non-attenders to Cervical Cancer Screening
The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic.
- Conditions
- Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection
- Trial name
- KOPRETINA (NCT04226313)
- Testing
- Self-sampling by Evalyn Brush, Self sampling by Evalyn Brush home or in GP´s clinic
- Where
- Czechia
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
Cervical Cancer, STI
Cervical Cancer Screening by Self-sampling in a Cohort of Younger Women in Ethiopia
The overall purpose of the project is to evaluate an algorithm for an HPV self-sampling based cervical cancer screening algorithm in a mid-size town in Ethiopia that could be applicable for nationwide implementation in low and…
- Conditions
- Cervical Cancer, STI, Human Papilloma Virus, Microbiota
- Trial name
- NCT05125380
- Testing
- VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine), VIA (Visual Inspection with Acetic acid)
- Where
- Ethiopia
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Lund University
Papilloma Viral Infection
Immunogenicity of Off-Schedule Dosing of HPV Vaccine
The purpose of this study is to gain a better understanding of the body's response to a human papillomavirus (HPV) (sexually transmitted disease), vaccine and booster shot.
- Trial name
- NCT01030562
- Where
- 7 sites in United States
- Volunteers
- 1,321 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HPV Infections
A Phase 1 Study of PV-001 9-valent Human Papillomavirus(HPV) Vaccine
Study Title: Evaluation of the Safety and Immunogenicity of a Third Dose of PV-001 in Healthy Women Aged 19-45 Objective: To assess the safety and antibody response of a third dose of PV-001 in healthy adult female participants.
- Trial name
- HPV (NCT07081334)
- Testing
- PV-001, PEV-001
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- POSVAX
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
Development of a Self-collection Device for Cervical Cancer Screening
Evaluation of a novel self-collection device for cervical cancer screening.
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus
- Trial name
- NCT05669911
- Testing
- Teal Health Self-Collection Device Group
- Where
- 6 sites in United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Teal Health, Inc.
Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection
Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening
This study aims to evaluate the vaccine effectiveness of 1 dose the nonavalent human papillomavirus (HPV) vaccine against HPV16, 18, 31, 33, 45, 52, and 58 infection among young adult women in Sweden participating in a nationwide…
- Trial name
- FASTER1DOSE (NCT07314307)
- Testing
- Gardasil 9 2 dose regimen
- Where
- Sweden
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Genital Warts, Human Papilloma Virus
Typing of Human Papilloma Virus (HPV) From Female Genital Warts
This is a longitudinal observational study of women presenting to Groote Schuur Hospital with genital warts. The study will evaluate the socio-demographic characteristics of the women using a structured questionnaire.
- Trial name
- NCT01192282
- Testing
- Medical / Surgical Treatment
- Where
- South Africa
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Infections, Papillomavirus
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine…
- Trial name
- NCT00586339
- Testing
- Cervarix
- Where
- South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Human papillomavirus (HPV) infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18)…
- Trial name
- NCT00492544
- Testing
- Cervarix™ (HPV-16/18 L1 VLP AS04)
- Where
- 5 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in…
- Trial name
- NCT01190189
- Testing
- GSK580299 (Cervarix)
- Where
- 28 sites in United States, Canada
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Cervical Dysplasia
Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study
In Singapore, the current cervical cancer screening uptake among women in Singapore has remained at low 50% since its introduction in 2004.
- Conditions
- Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection
- Trial name
- NCT03813576
- Testing
- Self-collected HPV vaginal swab
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Papillomavirus Infections
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
- Trial name
- NCT00157950
- Testing
- Gardasil™
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
- Trial name
- NCT00973362
- Testing
- APTIMA HPV Assay, FDA-Approved HPV DNA Test
- Where
- 17 sites in United States
- Volunteers
- 12,896 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Infections, Papillomavirus
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00169494
- Testing
- HPV-16/18 L1/AS04
- Where
- 17 sites in Denmark, Estonia and 4 more
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC